Greg Behar

Board Member

Greg started his career in 1993 in an Engineering company in Switzerland and joined Nestlé in 1995 in Brazil and Switzerland before working at Novartis Pharma in Spain and at global headquarters in Switzerland. In 2010, he joined Boehringer Ingelheim where he was responsible for various regions and for the Cardiovascular and Metabolic franchise. In 2011, he was appointed President & CEO of Boehringer Ingelheim Pharmaceuticals, Inc. in the USA, responsible for sales of USD 5.5 billion and over 5,000 employees. On October 1st, 2014, Greg was appointed CEO for Nestlé Health Science SA, a wholly-owned subsidiary of Nestlé SA. He is also a Board member of Cerecin, Inc., Seres Therapeutics, Inc., Axcella Health Inc. and Aimmune Therapeutics, Inc. Mr. Behar obtained a Master of Science in Mechanical Engineering and Manufacturing from the EPFL, near Lausanne, coupled with an MBA from INSEAD in France.